Market closed·Syncing…
Market closed · Close · 19 Nov

Tatva Chintan Pharma Chem Limited TATVAshare price and chart

Tatva Chintan Pharma Chem closed at ₹1,637.20 on 19 November 2026, down 0.71% on the day. The 52-week range is ₹1,044.10 to ₹2,113.60.

₹1,637.20The price one share last traded at, in rupees.▼ 0.71% · ₹11.71
52-wk low ₹1,04455% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹2,114

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on TATVA

Real prices, every charge counted. Pick one or write your own.
What Tatva Chintan Pharma Chem Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Tatva Chintan Pharma Chem makes specialty chemicals, with structure directing agents 40.7% of its turnover, pharmaceutical and agrochemical intermediates and other specialty chemicals 33.1%, phase transfer catalysts 23.1%, and electrolyte salts and solutions 2%, from two plants.

1
1Sector

Chemicals & Petrochemicals

2
2What it sells

Structure directing agents, phase transfer catalysts, intermediates, electrolyte salts

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
44.3Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
51%Near average
today 51%20d avg 43.2%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.▼ 5.2%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+14.6%1 monthHow much the share price has changed over the period.▼ 13.4%3 monthsHow much the share price has changed over the period.▼ 0.6%1 yearHow much the share price has changed over the period.+10.6%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.54.7%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹3,830 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.60.9xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.5.5%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.4.70xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.7.1%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.41.3xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.12%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.21xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-16.3%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Specialty Chemicals · 90 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.60.86vs 25.03 median
Cheapest: BIOPOL 4.07Priciest: INDOKEM 785.75
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.9.68%vs 7.21% median
Lowest: DIAMINESQ -19.71%Highest: SUDEEPPHRM 26.58%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.75.94%vs 26.34% median
Lowest: AGASTYAEN -85.82%Highest: ARVEE 622.45%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 19 Oct 2026), sales rose 75.9% from a year earlier to ₹217 cr and profit rose 116.3% to ₹21.5 cr.

Worth watching
  • Return on equity stayed under 10% from FY24 to FY26 (highest 5.5%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 20 results, the share rose on 5 and fell on 15, and moved by 3% or more on 15.

+21%
-21%
Q2 FY23Q2 FY24Q2 FY25Q2 FY26Q2 FY27

Q2 FY27: results filed 19 Oct 2026. The share went from its close on 16 Oct 2026 to its close on 21 Oct 2026 -2.77%.

Dividend historyCash the company has paid per share, year by year.

₹120 / year
Paid 5 of 5 yrs
on ₹1 lakh at today's price · 0.12% yield · ₹2/share
What each year paid, on ₹1 lakh
122
122
122
61
122
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹2.00 per share, about ₹122 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
-8.6%a year, over 5 years
1 yr
+6.8%
3 yr
+2.9%
5 yr
-8.6%

Held for 5 years this compounded at -8.6% a year. The last twelve months were up +6.8%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
72.02%promoter holding, as of 2026-09-30-7.2 pts since 2021
Promoter share since listing
2021-0972.02% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
72.0%
20.4%
Promoter72.0%Foreign (FII)4.4%Domestic (DII)3.2%Public & others20.4%
Who is buying, who is leavingJun 25 to Sep 26
Promoter72.0%steady
Foreign (FII)4.4%+1.1 pts
Domestic (DII)3.2%-1.9 pts

Each line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Insider tradesPurchases and sales of the company's own shares by promoters, directors and senior staff.

Last 18 months
Buy
Ajay Mansukhlal Patel
Promoters · 09-Feb-2026 18:17
7.2 L sh
Sell
Ajay Mansukhlal Patel (HUF)
Promoter Group · 09-Feb-2026 18:17
7.2 L sh

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Copy of Newspaper Publication20-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Copy of Newspaper Publication

General Updates19-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Updated Investor Presentation.

Investor Presentation19-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Investor Presentation

Updates19-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange regarding 'Earnings call scheduled to be held on Monday, 19 October 2026 at 05:00 p.m. (IST) has been cancelled due to unforeseen circumstances. '.

Outcome of Board Meeting19-Oct-2026

Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Analysts/Institutional Investor Meet/Con. Call Updates16-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates13-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet

Certificate under SEBI (Depositories and Participants) Regulations, 201806-Oct-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Shareholders meeting26-Sep-2026

Tatva Chintan Pharma Chem Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results.

Shareholders meeting25-Sep-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026

Trading Window23-Sep-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Analysts/Institutional Investor Meet/Con. Call Updates17-Sep-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet

Analysts/Institutional Investor Meet/Con. Call Updates08-Sep-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet

Credit Rating08-Sep-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Credit Rating

Copy of Newspaper Publication28-Aug-2026

Tatva Chintan Pharma Chem Limited has informed the Exchange about Copy of Newspaper Publication

Backtest idea · TATVAMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on TATVA
Backtest idea · TATVALower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on TATVA
Backtest idea · TATVASupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on TATVA
Your own ideaWrite a rule for TATVA in plain English“Buy TATVA when …”
Start writing
Buy the dip on TATVABuy when RSI(14) drops below 30
52-week high breakout on TATVABuy when closes at a 52-week high
Golden cross on TATVABuy when 50-day EMA crosses above 200-day
Stochastic oversold on TATVABuy when stochastic %K drops below 20
Pullback in an uptrend on TATVABuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹3,830 cr
Larger than 68% of 90 peers
sector middle ₹1,172 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
60.9x
Higher than 89% of 79 peers
sector middle 25.0x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
4.7x
Higher than 75% of 80 peers
sector middle 2.6x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
5.5%
Lower than 65% of 66 peers
sector middle 8.2%
FY23 8.8%FY26 5.5%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
7.1%
Lower than 72% of 78 peers
sector middle 11.5%
FY23 7.8%FY26 7.1%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.21
Lower than 56% of 79 peers
sector middle 0.25
FY23 0.33FY26 0.15
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.1%
Around the middle of 90 peers
sector middle 0.2%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+75.9%
Higher than 88% of 80 peers
sector middle +26.3%
FY25 -2.7%FY26 32.2%

Peers are the listed companies in the exchange's own industry group: Specialty Chemicals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.18.4%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+116.3%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹506 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹42 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹8.3 as profit. Other income added ₹0.7.

Where it wentPer ₹100 of sales
Running costs₹81.6Depreciation₹7.3Interest₹0.6Tax₹3.0Profit₹8.3
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+5.3%-+75.9%
Profit▼ 24.0%-+116.3%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹6 Cr, after ₹114 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹31 Cr
Investing-₹116 Cr
Lenders and shareholders+₹79 Cr
Net change in cash-₹6 Cr
Operating cash per ₹100 of profit
₹61FY23₹323FY24₹432FY25₹75FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY24FY25FY26
Sales growthSales in this financial year against the previous one.·-2.7%32.2%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.17.3%9.0%18.4%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.7.7%1.5%8.3%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.4.8%0.8%5.5%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.7.0%1.2%7.1%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.02x0.05x0.15x
Interest coverHow many times the company's profit before interest could pay its interest bill.7.7x6.8x20.7x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · TATVAStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on TATVA
Backtest idea · TATVAPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on TATVA
Backtest idea · TATVABuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on TATVA
Backtest idea · TATVA52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on TATVA
Backtest idea · TATVAGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on TATVA
MACD momentum on TATVABuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on TATVABuy when closes below the lower Bollinger band
Supertrend rider on TATVABuy when supertrend turns up
Buy the dip on TATVABuy when RSI(14) drops below 30
52-week high breakout on TATVABuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Specialty Chemicals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
PIDILITIND
Pidilite Industries Limited
1.61 L cr59.9x14.3x23.5%31.8%0.0016.8%+20.9%0.73%
SRF
SRF Limited
74,518 cr32.6x4.9x13.8%14.2%0.3412.5%+34.7%0.40%
FLUOROCHEM
Gujarat Fluorochemicals Limited
54,690 cr81.0x6.5x7.5%9.8%0.2611.4%+45.5%0.06%
NAVINFLUOR
Navin Fluorine International Limited
52,334 cr57.5x11.7x20.1%21.4%0.2722.4%+57.0%0.16%
AETHER
Aether Industries Limited
22,517 cr90.1x8.7x9.8%11.6%0.2519.2%+26.2%0.00%
DEEPAKNTR
Deepak Nitrite Limited
21,172 cr19.9x3.3x9.8%11.5%0.2510.9%+61.8%0.48%
FINEORG
Fine Organic Industries Limited
16,731 cr34.7x5.7x16.8%22.0%0.0518.5%+22.1%0.20%
AARTIIND
Aarti Industries Limited
16,565 cr27.9x2.6x7.3%7.0%0.825.6%+74.7%0.22%
ANURAS
Anupam Rasayan India Limited
15,108 cr83.8x3.0x5.8%7.4%0.348.9%+10.2%0.11%
ATUL
Atul Limited
14,909 cr19.3x2.3x11.5%14.9%0.0211.3%+20.9%0.59%
PRIVISCL
Privi Speciality Chemicals Limited
13,809 cr37.0x8.8x24.8%22.2%0.6113.4%+12.0%0.42%
SUDEEPPHRM
Sudeep Pharma Limited
13,691 cr71.9x14.3x19.4%22.5%0.1926.6%+20.9%0.12%
BASF
BASF India Limited
12,561 cr21.0x2.9x11.1%15.2%0.003.5%+19.4%0.86%
VINATIORGA
Vinati Organics Limited
12,162 cr29.5x3.7x14.9%19.8%0.0016.4%+23.6%0.72%
ELANTAS
Elantas Beck India Limited
9,554 cr51.1x----18.9%+22.5%0.06%
JUBLINGREA
Jubilant Ingrevia Limited
9,138 cr25.8x2.8x9.2%11.0%0.277.1%+24.4%0.87%
NEOGEN
Neogen Chemicals Limited
8,678 cr192.9x5.5x3.6%6.6%0.994.0%+41.8%0.03%
ALKYLAMINE
Alkyl Amines Chemicals Limited
8,045 cr32.5x4.9x12.3%16.6%0.0114.1%+26.1%0.64%
GALAXYSURF
Galaxy Surfactants Limited
7,777 cr19.1x2.6x10.5%13.4%0.086.5%+36.5%1.82%
CLEAN
Clean Science and Technology Limited
7,407 cr31.8x4.4x15.3%20.7%0.0022.5%+22.4%0.86%
BALAMINES
Balaji Amines Limited
6,086 cr25.6x2.9x8.1%11.0%0.0714.6%+37.3%0.59%
ACI
Archean Chemical Industries Limited
5,395 cr53.8x2.8x5.5%7.8%0.288.3%+27.5%0.57%
FCL
Fineotex Chemical Limited
5,245 cr31.5x5.4x14.9%18.3%0.0113.2%+181.5%0.11%
PRASOLCHEM
Prasol Chemicals Limited
4,597 cr-7.5x--0.11--0.00%
FOSECOIND
Foseco India Limited
4,490 cr38.0x4.2x10.2%14.5%0.0014.4%+67.3%0.42%
YASHO
Yasho Industries Limited
4,361 cr50.4x8.5x5.8%9.1%1.207.8%+89.7%0.01%
LXCHEM
Laxmi Organic Industries Limited
4,280 cr24.9x2.0x4.1%4.7%0.344.9%+54.7%0.19%
EPIGRAL
Epigral Limited
4,077 cr14.3x1.7x16.1%15.7%0.2410.2%+27.0%0.53%
CHEMPLASTS
Chemplast Sanmar Limited
3,953 cr-2.5x-14.6%-3.6%1.11-7.6%+28.1%0.00%
TATVA
Tatva Chintan Pharma Chem Limited
3,830 cr60.9x4.7x5.5%7.1%0.219.7%+75.9%0.12%
VISHNU
Vishnu Chemicals Limited
3,725 cr24.4x3.3x14.2%16.3%0.628.8%+7.1%0.05%
STYRENIX
Styrenix Performance Materials Limited
3,252 cr12.9x2.2x14.4%15.9%0.166.8%+24.4%2.49%
JUBLCPL
Jubilant Agri and Consumer Products Limited
2,736 cr26.1x5.2x32.6%41.1%0.335.1%+15.0%0.00%
DDEVPLSTIK
Ddev Plastiks Industries Limited
2,528 cr11.6x2.3x21.8%31.1%0.066.3%+43.8%0.72%
ROSSARI
Rossari Biotech Limited
2,371 cr15.5x1.7x11.8%14.7%0.265.7%+19.0%0.12%
NOCIL
NOCIL Limited
2,318 cr29.7x1.3x3.1%4.4%0.005.3%+33.2%1.08%
SHK
S H Kelkar and Company Limited
1,758 cr18.6x1.2x5.3%7.9%0.683.7%+14.9%0.79%
INDOKEM
Indokem Limited
1,753 cr785.8x----1.2%+17.3%0.00%
NITTAGELA
Nitta Gelatin India Limited
1,584 cr15.3x----17.5%+1.5%0.40%
VIDHIING
Vidhi Specialty Food Ingredients Limited
1,532 cr25.4x4.2x15.6%18.8%0.1512.1%+82.0%0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-13.5
+6.0
-14.0
+24.6
-13.6
+5.4
+49.7
-9.0
+9.7
-7.9
-0.4
·
+22.7%
11m
2025
-11.1
-12.5
-2.1
+4.0
+28.2
+6.3
+21.6
-10.9
-2.7
+40.6
+2.5
-8.4
+50.0%
2024
-16.4
-9.3
-11.2
+13.9
-15.8
+6.9
-9.6
-3.9
+9.5
-19.3
+4.5
+0.5
-44.5%
2023
-3.5
-7.6
-12.9
+3.9
-4.4
+11.2
-10.9
+4.9
-8.1
-6.6
+2.0
+6.2
-25.5%
2022
-8.0
-12.9
+8.5
+0.5
+0.2
+0.8
-1.1
+5.3
+3.2
-4.4
-7.5
-3.3
-19.0%
2021
·
·
·
·
·
·
·
-9.1
+6.3
+14.3
-6.0
+12.7
+17.1%
5m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2025-10-15MUSIGMA SECURITIES · bulkSELL1,43,717₹1,262.51₹18.14 Cr
2025-10-15MUSIGMA SECURITIES · bulkBUY1,43,717₹1,262.14₹18.14 Cr
2025-10-15GRAVITON RESEARCH CAPITAL LLP · bulkSELL1,33,709₹1,212.74₹16.22 Cr
2025-10-15GRAVITON RESEARCH CAPITAL LLP · bulkBUY1,33,709₹1,210.89₹16.19 Cr
2025-07-25GRAVITON RESEARCH CAPITAL LLP · bulkBUY2,17,066₹1,152.08₹25.01 Cr
2025-07-25GRAVITON RESEARCH CAPITAL LLP · bulkSELL2,17,066₹1,153.92₹25.05 Cr
2025-07-25MUSIGMA SECURITIES · bulkSELL1,17,833₹1,171.36₹13.80 Cr
2025-07-25MUSIGMA SECURITIES · bulkBUY1,17,833₹1,170.74₹13.80 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test TATVA. “Buy TATVA when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free